NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE)

Not Yet RecruitingNA

Sponsor: University of Minnesota

Conditions: Cardiotoxicity, Cancer, Cardiac Arrhythmia, Left Ventricular Dysfunction, Breast Cancer

Interventions: Mobile Cardiac Telemetry, Wearable Cardiac Monitor

Countries: United States

This pilot study will evaluate the validity and feasibility of ambulatory cardiac monitoring to identify markers of cardiotoxicity in adults undergoing cancer treatment. Participants with breast cancer, hematologic malignancy, or multiple myeloma will receive usual care plus two wearable patch monitors: mobile cardiac telemetry using the BodyGuardian Mini Plus ambulatory ECG monitor and an investigational wearable cardiac monitor that records heart sounds. The study will assess arrhythmias detected by mobile cardiac telemetry and explore whether heart sounds are associated with echocardiographic findings and cardiac biomarkers. Participants will wear the devices during cancer treatment, with monitoring periods at baseline and possible repeat monitoring at 6-month and 12-month study visits.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Diagnosis of breast cancer, hematologic malignancy including leukemia or lymphoma, or multiple myeloma
* At least 18 years of age
* Capable of understanding and willing to sign a consent form for this study

Exclusion Criteria:

* Known allergy to adhesive patches used for ambulatory EKG monitoring
* Children
* Cognitively challenged individuals
* Prisoners
* Active service military personnel

Locations (1)

Minneapolis, Minnesota, United States